Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling $245M

Published on :

Ascentage Pharma (6855.HK), a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics (1801.HK, “Innovent”), today announced a multifaceted strategic collaboration.

NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV

Published on :

TTC is planning a technology opportunities webinar on July 13, 2021 from 11:00 am – noon, EST. Attendees will hear from the NCI’s Dr. Genoveffa Franchini about a new HIV [….]

Gaithersburg’s Sirnaomics Secures $105 Million in Series E Financing to Fund Development of Novel RNAi Therapeutics

Published on :

Proceeds to Fund Development of Novel RNAi Therapeutics for Cancers, Viral Infections, Fibrosis, and Metabolic Diseases

NCI Technology Opportunities Webinar: “Complete Tumor Regression Seen in Colon Cancer and Leukemia Animal Models with a Novel High Efficacy Fluorinated Cytidine Therapeutic Compound”

Published on :

The National Cancer Institute (NCI), Technology Transfer Center (TTC) will host a webinar to highlight a cancer therapeutic technology for collaborative development and/or licensing. The webinar presented by the technology inventor, Dr. Joel Morris, will highlight NCI’s novel, therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia. Studies indicated that the therapeutic compound can produce complete regression in xenograph mouse models with minimal effects on body weight. Registration is free.

Gaithersburg’s miRecule Inc. closes $5.7M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy

Published on :

miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.

WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer

Published on :

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today announced the appointment of Co-Founder Kimberly Noonan, PhD, MPH, to Executive Vice President, Chief Science & Technology Officer. In this role, Dr. Noonan’s leadership will expand to include WindMIL’s efforts in manufacturing and manufacturing science and technology (MS&T).

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Published on :

Partnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate

Rockville’s MacroGenics Enters Research Collaboration with Sweden’s Alligator Bioscience to Develop a Novel Immunotherapy

Published on :

Under the joint research collaboration agreement, which covers activities from candidate drug generation up until IND-enabling studies, each company will be responsible for its own costs. The parties may continue further development of the resulting bispecific molecule under a separate co-development collaboration and licensing agreement.

Gaithersburg’s VLP Therapeutics raises $16M Series A for cancer treatment vaccine R&D

Published on :

VLP Therapeutics raises $16M Series A for cancer treatment vaccine R&D GAITHERSBURG, Md., March 15, 2021 /PRNewswire/ — US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on March 15 that it has raised US$16 million in a [….]

Baltimore’s Personal Genome Diagnostics and Fox Chase Cancer Center Announce Partnership to Broaden Liquid Biopsy Applications in Oncology Clinical Research

Published on :

Personal Genome Diagnostics and Fox Chase Cancer Center Announce Partnership to Broaden Liquid Biopsy Applications in Oncology Clinical Research BALTIMORE, Md.–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer [….]